ClinicalTrials.gg
CompletedNCT05267639Updated Sep 17, 2026Results posted

Clinical Outcomes With Passive MPKs vs. Powered Prosthetic Knees

An interventional study of Power Knee in Amputation, Amputation; Traumatic, Leg, Lower and Limb; Absence, Congenital, Lower, sponsored by Liberating Technologies, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Liberating Technologies, Inc. · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this proposed project is to gather community-based data from the K4-level Transfemoral Amputee (TFA) population to aid in evidence-based prescription of powered prosthetic knees (i.e., choosing the right device to maximize the benefit for each patient). The investigators envision that this Level 1 submission will transition into a larger follow-on Level 2 trial that will explore a larger spectrum of patient populations (K2-K4), as well as testing additional Power Knees currently in development that are expected to become commercialized in the near future. The investigators intend to use this Level 2 trial data to guide the implementation of effective prescriptions towards those that can benefit most from a given device and limit prescription to those who would not see benefit in order to ensure the most judicious use of Department of Defense (DoD) and Veteran's Affairs healthcare dollars. The findings will also be shared with the research community to help drive the design of future devices by identifying what features and functions are most beneficial to which patient populations when the devices are used outside of the laboratory. In summary, more community-based data on how powered prosthetic knees compare with MPKs is needed to allow for improved clinical decision making and clinical outcomes.

Read the detailed description

The goal of this proposed project is to gather community-based data from the K4-level Transfemoral Amputee (TFA) population to aid in evidence-based prescription of powered prosthetic knees (i.e., choosing the right device to maximize the benefit for each patient). The investigators envision that this Level 1 submission will transition into a larger follow-on Level 2 trial that will explore a larger spectrum of patient populations (K2-K4), as well as testing additional Power Knees currently in development that are expected to become commercialized in the near future. The investigators intend to use this Level 2 trial data to guide the implementation of effective prescriptions towards those that can benefit most from a given device and limit prescription to those who would not see benefit in order to ensure the most judicious use of Department of Defense (DoD) and Veteran's Affairs healthcare dollars. The findings will also be shared with the research community to help drive the design of future devices by identifying what features and functions are most beneficial to which patient populations when the devices are used outside of the laboratory. In summary, more community-based data on how powered prosthetic knees compare with MPKs is needed to allow for improved clinical decision making and clinical outcomes.

This study will focus on investigating the tradeoffs between the commercially available Ossur Power Knee and traditional MPKs to identify the prosthetic knee that is best suited for K4 users during different tasks. The investigators will assess measured, observed, and self-reported outcomes achieved through real-world use of the prosthetic knees.

The results of this study will (1) provide initial data to inform the evidence-based prescription and use of powered knee technologies for K4-level individuals with sound scientific data, (2) provide pilot data for a larger clinical trial to further inform the evidence-based prescription of powered knee technologies to other K-levels to maximize patient benefit while optimizing device cost and thereby influencing clinical practice and informing policy decisions, and (3) provide data that can be disseminated to other researchers to inform the design of future powered prosthetic knees by understanding the needs of users and identifying the features and functions that are most valuable to this patient population as well as the capabilities and limitations of current devices.

The primary outcome measures for each aim are outlined as follows:

  • [Mobility Primary Outcome]: daily number of steps taken
  • [Safety Primary Outcome]: Activities-Specific Balance Scale
  • [Wellbeing Primary Outcome]: PEQ-Well-Being (PEQ-WB)

The exploratory data collected in the in-clinic and take-home portions of this study will include number of steps and number of self-reported falls, and a series of standard outcomes measures, such as: 6MWT, SAI, RAI, PROMIS-PF short form, PLUS-M, TUG, ABC, RPE, PROMIS-Fat, fall count, PROMIS-29, ODI, PEQ-WB, and PROMIS-APSRA short form.

The investigators plan to perform a pilot longitudinal randomized crossover study to compare the powered knee and passive microprocessor knees in individuals with unilateral transfemoral amputation. The two interventions, or conditions, to be tested are: (A) Ossur PK and (B) a standard MPK. For this study the investigators will recruit individuals who are currently MPK users; therefore, for the MPK condition, they will wear their usual prosthesis (e.g. Otto Bock C-leg, Össur Rheo, etc) as they represent the current standard of care. This will be recorded as a potential confounder in post-hoc analysis. Each participant will be provided with prosthetic knees for the powered knee condition.

The order these conditions are tested in will be randomized across subjects. Block randomization using a previously developed custom software based on random number generation will be used to equally distribute the subjects into the 2 possible intervention orders (AB or BA). For each condition, the subject will be trained on and acclimated to the device during the first month of the take-home period, and then will continue to wear it at home after training for a total of three months per condition. There may be seasonal effects due to the timing of when the various test conditions are administered, however, the investigators plan to offset these effects with condition randomization, multiple site testing, and staggered start times.

Testing will consist of test sessions, training sessions, at-home wear of the device, and functional and self-report assessment at the end of each intervention condition. If the subject's current foot is not compatible with the Power Knee, they will be provided with a commercially available prosthetic foot for the study. In this case, the subject will be given an initial acclimation period of 1 month on the new foot before starting interventional testing.

After receiving IRB and HRPO (US Army Human Research Protection Office) approval, subjects will be recruited and screened for eligibility. If they are eligible and decide to participate, they will be scheduled for their first site visit. They will either be consented over the phone before their first site visit or at the first site visit. If over the phone, study staff will use the telephone script to confirm eligibility and guide the subject through consent form details. Subjects will be provided the informed consent form to read through entirely before signing, and are encouraged to ask questions at any time.

Prior to each condition, each subject will be fit and aligned on the knee by a trained certified prosthetist. An activity monitor (such as the GeneActiv™) will be worn by the subject. As the investigators have done in prior studies, the investigators will use the activity monitor to track the number of steps the subjects take in each condition. Each subject will wear the same foot for all study periods for comparability between the two knee conditions.

The subject will wear the knee being tested at home for three months. During the first month of each condition, subjects will be given time to acclimate to the knee being tested. Before and after each condition, the subject will complete a battery of outcomes and self-report surveys. Subjects will participate in at least two, but up to eight, 1 hour training sessions per knee. At a minimum, each subject will receive one training session to learn how to properly use each device for a variety of daily activities and a second session to demonstrate retention of the learned skills. The subject will continue training until they show retention of the understanding and/or proficiency of the device functions or until they have received eight training sessions, whichever comes first. After 8 training sessions, they will have completed all of the available training and will therefore continue with the study at their current proficiency level. For the powered knee condition, the investigators will work with trained and experienced clinicians, consulting prosthetic knee manufacturers as needed, to develop the training protocol and determine proficiency. At the last training session, the subject will complete a subset of the outcomes and self-report measures in order to collect and compare data from before and after the subject gets trained on each knee condition.

After the training visits are completed, subjects will be asked to continue to wear the knee full time for the remainder of the three month take-home period. Through Hanger's current patient care system, the investigators will have the ability to push out a digital to the patient's phone asking them whether they have experienced a recent fall. If they respond positively that they had a fall, follow up questions can be asked to get more specific details about the fall. After three months of at-home wear, the subject will return for the second test visit. During that visit, functional tests and self-report surveys will be administered. At the completion of the second test visit (Period 1), the subject will then be fit and aligned on the prosthetic knee condition for Period 2. The training, at home wear, and in-clinic assessments will be repeated for the next knee condition.

02

Conditions studied

  • Amputation
  • Amputation; Traumatic, Leg, Lower
  • Limb; Absence, Congenital, Lower
  • Prosthesis User
  • Lower Limb Amputation Above Knee (Injury)
  • Amputation; Traumatic, Leg: Thigh, Between Hip and Knee

Browse trials for

Keywords

  • amputee
  • lower limb amputee
  • transfemoral amputee
  • prosthetic knee
  • power knee
  • microprocessor knee
  • MPK
  • Ossur
  • lower limb prosthesis user
03

In context

Wounds and Injuries

2,217 studies on the registry are indexed under Wounds and Injuries; 441 are open to participants now.

This study's enrollment of 13 is below the median of 70 across 1,424 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Liberating Technologies, Inc. is the lead sponsor of 15 studies on the registry; 4 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are at least 18 years old
  • Unilateral transfemoral prosthesis user (limb absence between the knee and hip)
  • Current user of a microprocessor-controlled knee (MPK)
  • Have adequate clearance between distal end and ground for necessary knee and foot components
  • Medicare Functional Classification Level (K-Level): 4
  • Socket-Comfort Score: 6 or above to ensure adequate socket fit
  • PLUS-M T-score of 55 or above
  • Six months or more experience on a prosthesis
  • Body weight between 50kg and 116kg (110lbs - 256lbs)

Exclusion criteria

Exclusion Criteria:

  • Present injuries to residual limb or contralateral leg affecting functional ability
  • Socket issues/changes in the last 6 weeks
  • Users with bone-anchored implants

Subjects can be excluded at the discretion of the investigator for other unforeseen disqualifying criteria (such as specific cognitive issues, etc.). Subjects in this study will not be discriminated by sex/gender or race/ethnicity.

Using a knee that the subject is unfamiliar with may increase the risk of falling. Therefore, pregnant women should not participate in the study and will be screened by self-disclosure.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • No intervention
    Control (MPK)

    The subject will wear their usual Microprocessor Knee (MPK) for 3 months, as well as in the lab to complete outcome measures.

  • Experimental
    Power Knee

    The subject will wear the Ossur PK in place of their usual MPK for 3 months, as well as in the lab to complete outcome measures.

    Device: Power Knee

Interventions

  • DevicePower Knee

    Newest version of the commercially-available Power Knee developed by Ossur.

    Also known as: Ossur Power Knee, Ossur Power Knee III, PK, PK3

06

What researchers measure

Primary outcomes

  1. Daily Step Count

    Prior to each condition, each subject will be fit and aligned on the designated knee by a trained certified prosthetist. An activity monitor (such as the GeneActiv™) will be worn by the subject for each intervention period during the final month of the condition. Similar to prior studies, the investigators will use the activity monitor to track the number of steps the subjects take in each condition per day. The number of steps per day are averaged over the final month in each condition. A higher value indicates a better outcome.

    Time frame: 1 Month

  2. Activities-Specific Balance Confidence Scale (ABC) - Measuring Change From Baseline

    Activities-specific balance confidence (ABC) scale is a structured questionnaire that measures an individual's confidence during ambulatory activities without falling or experiencing a sense of unsteadiness. It consists of 16 questions gauging the individual's confidence while doing activities, from 0 (no confidence) to 4 (complete confidence). Therefore, the total score ranges from 0 to 64, with a higher value indicating a better outcome. This survey will be given at the end of each study condition (2 conditions, 3 months per condition). This survey will be administered as a part of the master questionnaire. Analysis is reported in % of balance confidence, which is found by taking their average of all questions (sum up all questions and divide by total number of questions) and dividing that average by 4.

    Time frame: At the end of each 3 month condition

  3. PEQ-Well Being (PEQ-WB) - Measuring Change From Baseline

    The version of the PEQ which will be administered consists of 2 questions in 1 category (well being). For purposes of easier administration, the investigators have adopted the modified 10-point ordinal scale version of the PEQ-WB (scale 1-10, where 1 is the worst and 10 is the best relative to the questions being asked). This survey will be given at the end of each study condition (2 conditions, 3 months per condition). This survey will be administered as a part of the master questionnaire. The reported result is the average of the 2 questions in the PEQ-WB. The range of this reported result is 1-10, where a higher value indicates a better outcome.

    Time frame: At the end of each 3 month condition

07

Results

Posted Jun 26, 2025
Limitations and caveats
Limited data for the powered knee condition reduces the generalizability of these results

Participant flow

Participant flow — Overall Study
MilestoneControl (MPK), Then Power KneePower Knee, Then Control (MPK)
Started76
Completed66
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryDaily Step Count

Prior to each condition, each subject will be fit and aligned on the designated knee by a trained certified prosthetist. An activity monitor (such as the GeneActiv™) will be worn by the subject for each intervention period during the final month of the condition. Similar to prior studies, the investigators will use the activity monitor to track the number of steps the subjects take in each condition per day. The number of steps per day are averaged over the final month in each condition. A higher value indicates a better outcome.

Time frame:
1 Month
Reported as:
Mean · Steps/day
Daily Step Count
Steps/dayControl (MPK)Power Knee
Daily Step Count5747 ± 32123162 ± 1031
PrimaryActivities-Specific Balance Confidence Scale (ABC) - Measuring Change From Baseline

Activities-specific balance confidence (ABC) scale is a structured questionnaire that measures an individual's confidence during ambulatory activities without falling or experiencing a sense of unsteadiness. It consists of 16 questions gauging the individual's confidence while doing activities, from 0 (no confidence) to 4 (complete confidence). Therefore, the total score ranges from 0 to 64, with a higher value indicating a better outcome. This survey will be given at the end of each study condition (2 conditions, 3 months per condition). This survey will be administered as a part of the master questionnaire. Analysis is reported in % of balance confidence, which is found by taking their average of all questions (sum up all questions and divide by total number of questions) and dividing that average by 4.

Time frame:
At the end of each 3 month condition
Reported as:
Mean · Percentage of balance confidence
Activities-Specific Balance Confidence Scale (ABC) - Measuring Change From Baseline
Percentage of balance confidenceControl (MPK)Power Knee
Activities-Specific Balance Confidence Scale (ABC) - Measuring Change From Baseline83 ± 1783 ± 15
PrimaryPEQ-Well Being (PEQ-WB) - Measuring Change From Baseline

The version of the PEQ which will be administered consists of 2 questions in 1 category (well being). For purposes of easier administration, the investigators have adopted the modified 10-point ordinal scale version of the PEQ-WB (scale 1-10, where 1 is the worst and 10 is the best relative to the questions being asked). This survey will be given at the end of each study condition (2 conditions, 3 months per condition). This survey will be administered as a part of the master questionnaire. The reported result is the average of the 2 questions in the PEQ-WB. The range of this reported result is 1-10, where a higher value indicates a better outcome.

Time frame:
At the end of each 3 month condition
Reported as:
Mean · score on a scale
PEQ-Well Being (PEQ-WB) - Measuring Change From Baseline
score on a scaleControl (MPK)Power Knee
PEQ-Well Being (PEQ-WB) - Measuring Change From Baseline8.3 ± 1.68.0 ± 1.5

Adverse events

Collected over Adverse events were monitored/collected during each condition. With each condition lasting about 3 months, each participant was monitored for adverse events for about 6 months total. Adverse events were monitored/assessed at least every 2 weeks by phone call, with study staff checking in more frequently if participants reached out with questions. Participants were told to reach out to study staff immediately if adverse events did occur.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control (MPK)0/13 (0%)0/13 (0%)2/13 (15.4%)
Power Knee0/13 (0%)0/13 (0%)2/13 (15.4%)
Most frequent other events
Most frequent other events
EventControl (MPK)Power Knee
Phantom Limb PainSkin and subcutaneous tissue disorders0/131/13
Broken fingerMusculoskeletal and connective tissue disorders1/130/13
FallSkin and subcutaneous tissue disorders0/131/13
Ankle swellingSkin and subcutaneous tissue disorders1/130/13

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Control (MPK), Then Power KneePower Knee, Then Control (MPK)Total
<=18 years000
Between 18 and 65 years5510
>=65 years213
Sex: Female, Male
Sex: Female, Male(Participants)Control (MPK), Then Power KneePower Knee, Then Control (MPK)Total
Female011
Male7512
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Control (MPK), Then Power KneePower Knee, Then Control (MPK)Total
Hispanic or Latino022
Not Hispanic or Latino639
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Control (MPK), Then Power KneePower Knee, Then Control (MPK)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White6511
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)Control (MPK), Then Power KneePower Knee, Then Control (MPK)Total
United States7613
08

Study locations

2 sites
  • Liberating Technologies, Inc.
    Holliston, Massachusetts 01746, United States
  • Hanger Clinic
    Austin, Texas 78758, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Aug 2024, 27 months.

Results were first posted in Jun 2025, 9 months after primary completion.

Of 53 industry-sponsored interventional studies with no phase under Wounds and Injuries, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's 27 months is above that.

Counting every sponsor, half of 599 studies reached it within 24 months; a quarter within 9 and three quarters within 48.

Wounds and Injuries covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2021
First posted
Mar 4, 2022
StartActual
May 1, 2022
Primary completionActual
Aug 28, 2024
CompletionActual
Aug 28, 2024
Results first posted
Jun 26, 2025
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05267639
Lead sponsor
Liberating Technologies, Inc.
Collaborators
Hanger Clinic: Prosthetics & Orthotics
Responsible party
Jennifer Johansson (Principal Investigator, Liberating Technologies, Inc.) — Principal investigator
First posted
Mar 4, 2022
Start date
May 1, 2022
Primary completion
Aug 28, 2024
Completion
Aug 28, 2024
Results posted
Jun 26, 2025
Last update
Sep 17, 2026

Study contacts

Jennifer Johansson, MS
principal investigator · Liberating Technologies, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion